参考文献/References:
[1]邓明惠,候轩,张微,等.产ESBLs肺炎克雷伯菌药敏性和耐药基因表型分析[J].国际检验医学杂志,2020,41(16):1994-1998. [2]诸宏伟,臧欢欢,刘培培,等.肺炎克雷伯菌外排泵基因研究与耐药性的关系[J].检验医学与临床,2020,17(15):2133-2134,2139. [3]Juan CH,Chuang C,Chen CH,et al.Clinical characteristics, antimicrobial resistance and capsular types of community-acquired, healthcare-associated, and nosocomial Klebsiella pneumoniae bacteremia[J].Antimicrob Resist Infect Control,2019,8:1.[4]Chew KL,Lin RTP,Teo JWP,et al.Klebsiella pneumoniae in Singapore: Hypervirulent Infections and the Carbapenemase Threat[J].Front Cell Infect Microbiol,2017,7:515.[5]胡付品,郭燕,朱德妹,等.2019年CHINET三级医院细菌耐药监测[J].中国感染与化疗杂志,2020,20(3):233-243.[6]王珊珊,赵建平.2014-2018年耐碳青霉烯类肺炎克雷伯 菌分离及耐药率分析[J].中国抗生素杂志,2020,45(10):1058-1062.[7]薛娟,谢敏,周婷.耐碳青霉烯类肺炎克雷伯菌感染患者的全因死亡率分析[J].中国临床药理学杂志,2018,34(18):2220-2223.[8]尚红,王毓三,申子瑜,等.全国临床检验操作规程[M].北京:人民卫生出版社,2015:574-625.[9]倪语星.抗微生物药物敏感性试验规范[M].上海:上海科学技术出版社,2009.[10]Shiri N,Kira K,Alessandra C.Klebsiella pneumoniae: a major worldwide sourceand shuttle for antibiotic resistance[J].FEMS Microbiol Rev,2017,13:252-275. [11]王军大,杨华,赵建宁,等.糖尿病患者肺炎克雷伯杆菌肝脓肿并发血源性肺部感染 CT 征象回归分析[J].中国CT和MRI杂志,2020,18(9):69-72. [12]彭威军,赖晓全,谭莉,等.器官移植术后并发耐碳青霉烯类肺炎克雷伯菌医院感染的危险因素[J].中国感染控制杂志,2020,19(8):710-714. [13]夏雨,张兵.7781例疑似血流感染患者的血培养标本病原菌分布及药敏结果分析[J].山东医药,2020,60(3):82-85.[14]崔巧珍,张燕军,郭慧芳.2003-2012 年医院内肺炎克雷伯菌的耐药性监测[J].中国药物与临床,2014,14(4):554-556. [15]汪滢,李家斌.238 株肺炎克雷伯菌的临床分布和耐药分析[J].安徽医学,2012,33(6):652-654. [16]邓林强,陈益国,陈会,等.某院不同病区间由肺炎克雷伯菌引起血流感染的相关分析[J].中国抗生素杂志,2018,43(5):630-634.[17]詹玲玲,黄海霞,陈约慧,等.2013年至2015年1830株肺炎克雷伯菌感染的临床分布及耐药性分析[J].中国临床药理学杂志,2017,33(24):2579.[18]陈君灏,张雯霞,陈晨,等.肺炎克雷伯菌临床分离株的耐药性 与分子流行病学分析[J].实用药物与临床,2020,23(7):650-654.[19]张侃,刘长鑫,王博,等.呼吸内科耐碳青霉烯类肺炎克雷伯菌不同耐药基因型的临床特征分析[J].国际呼吸杂志,2020,40(3):167-171.[20]别立翰,马晨芸,蒋秀娣,等.耐碳青霉烯类肺炎克雷伯菌耐药基因分布情况及其同源性探讨[J].中国医药导刊,2019,21(2):110-114. [21]黄泽玉,郑光辉,吕虹,等.神经外科术后患者手术部位感染肺炎克雷伯菌和鲍曼不动杆菌分子流行病学研究[J].国际检验医学杂志,2020,41(15):1818-1821,1825. [22]鲁艳,刘东华.呼吸机相关性肺炎患者耐碳青霉烯类肺炎克雷伯菌病原菌分析及耐药性监测[J].临床肺科杂志,2020,25(6):853-856. [23]张爱荣,许青霞.2011年-2015年商丘市肺炎克雷伯菌临床分布及其耐药性研究[J].中国卫生检验杂志,2017,27(9):1344-1346,1350.[24]Laura E,Nieves L,Ibai L,et al.Infections by OXA-48- like-producing Klebsiella pneumoniae non-coproducing extended-spectrum beta-lactamase: Can they besuccessfully treated with cephalosporins[J].J Glob Antimicrob Resist,2019,19(2):28-31.[25]佘丹阳.广泛耐药革兰阴性菌感染的抗菌药物联合治疗:雪中送炭还是画蛇添足[J].中华结核和呼吸杂志,2019,42(7):495-499.[26]杨帆.《抗菌药物临床应用指导原则（2015年版）》解读[J].中华临床感染病杂志,2016,9(5):390-393.[27]Wang XJ,Wang Q,Cao B,et al.Retrospective observational study from a Chinese network of the impact of combination therapy versus monotherapy on mortality from Carbapenem-resistant enterobacteriaceae bacteremia[J].Antimicrob Agents Chemother,2019,63(1):e01511-e01518.[28]胡付品,郭燕,朱德妹,等.2017年CHINET中国细菌耐药性监测[J].中国感染与化疗杂志,2018,18(3):241-251.
相似文献/References:
[1]刘永瑞,张 妍,李秀英.肺炎克雷伯菌AmpC酶检测及抗生素选择[J].医学信息,2019,32(19):122.[doi:10.3969/j.issn.1006-1959.2019.19.039]
LIU Yong-rui,Zhang Yan,LI Xiu-ying.Klebsiella Pneumoniae AmpC Enzyme Detection and Antibiotic Selection[J].Journal of Medical Information,2019,32(20):122.[doi:10.3969/j.issn.1006-1959.2019.19.039]
[2]周晓玲,张嘉文,陈惠霞.2018-2020年某三甲医院金黄色葡萄球菌的临床分布及耐药现状分析[J].医学信息,2021,34(23):153.[doi:10.3969/j.issn.1006-1959.2021.23.046]
ZHOU Xiao-ling,ZHANG Jia-wen,CHEN Hui-xia.Clinical Distribution and Drug Resistance of Staphylococcus Aureus in a Tertiary Hospital from 2018 to 2020[J].Journal of Medical Information,2021,34(20):153.[doi:10.3969/j.issn.1006-1959.2021.23.046]
[3]杜 佳.2018年~2019年杭州某医院肺炎克雷伯菌耐药性分析[J].医学信息,2021,34(10):153.[doi:10.3969/j.issn.1006-1959.2021.10.044]
DU Jia.Analysis of the Resistance of Klebsiella Pneumoniae in a Hospital in Hangzhou from 2018 to 2019[J].Journal of Medical Information,2021,34(20):153.[doi:10.3969/j.issn.1006-1959.2021.10.044]
[4]陆 颖,朱志军,朱 梅.肺炎克雷伯菌的耐药性及其与生物膜形成的关系[J].医学信息,2021,34(13):65.[doi:10.3969/j.issn.1006-1959.2021.13.017]
LU Ying,ZHU Zhi-jun,ZHU Mei.Drug Resistance of Klebsiella Pneumoniae and Its Relationship with Biofilm Formation[J].Journal of Medical Information,2021,34(20):65.[doi:10.3969/j.issn.1006-1959.2021.13.017]